[Substantiation of the use of terrilytin in the treatment of spinal cord disorders in tuberculous spondylitis].

Experiments on mice and studies with organotype cultures of the spinal ganglion showed that terrilytin, a proteolytic enzyme had neurite stimulating activity and promoted regeneration of the spinal marrow tissue after affection (squeeze). On the basis of this property and a previously observed favourable effect of the enzyme on microcirculation, the capacity for more rapid rarefaction and elimination of caseous masses and prevention of excessive fibrosis, it was recommended for use in treatment of cerebrospinal disorders in tuberculous spondylitis. A procedure for the treatment was developed. The clinical trials with 46 patients (22 in the main group and 24 in the control group) showed high efficiency of the procedure.